article Open AccessTop 1% cited

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

British Journal of Ophthalmology · 2014 · Vol. 99(2) · pp. 220–226

Frank G. Holz(University of Bonn)Ramin TadayoniStephen BeattyAlan R. Berger(St. Michael's Hospital)Matteo Giuseppe Cereda(University of Milan)Rafael CortezCarel B. Hoyng(Radboud University Nijmegen)Philip Hykin(University College London)Giovanni Staurenghi(University of Milan)Stephanie Heldner(Bayer (Germany))Timon Bogumil(Bayer (United States))Theresa Heah(Bayer (United States))Sobha Sivaprasad✉

View via DOI Full-text PDF

Abstract

NCT01447043.

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic ConditionsMedicineVisual acuityRanibizumabMacular degenerationOphthalmologyObservational studyRetrospective cohort studyClinical trialSurgeryBevacizumab

MeSH terms

RanibizumabAgedAged, 80 and overCanadaEuropeFemaleHumansMaleMiddle AgedRetrospective StudiesVenezuelaVisual AcuityRetreatmentAngiogenesis InhibitorsTomography, Optical Coherence

Funding

Pfizer
Alimera Sciences
National Institute for Health and Care Research
Bayer HealthCare
Carl Zeiss Meditec AG
Heidelberg Engineering
Servier
Genentech
Allergan
National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology

Citations

602

FWCI

26.49

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration